



Pharmaceuticals Ltd

**FOR IMMEDIATE RELEASE**

**Results of Migraine Clinical Trial Presented at 19<sup>th</sup> World Congress of Neurology**

[Rangiora, New Zealand] – [30 October 2009]—Results were presented today to the 19<sup>th</sup> World Congress of Neurology in Bangkok, Thailand indicating positive results with Migco's MGX 008 amongst a group of migraine patients refractory to current pharmacologic treatments.

The trial was conducted by Dr. Sirichai Chayasiribon M.D.,FAAN, at the Department of Neurology, Southern California Kaiser Permanente Medical Group In Los Angeles. Treatment was associated with a significant reduction ( $p < 0.001$ ) in migraine frequency, headache severity and disability related to migraine as measured by MIDAS (Migraine Disability Assessment). 18 out of 34 patients responded to treatment and the results were similar to a pilot study published in the a leading science journal *Headache* in 2006.

“These latest results are encouraging and confirm that further larger scale studies are commercially warranted”, said Larry Stenswick, CEO of Migco Pharmaceuticals. “There remains an immense need for therapeutic products that can reduce the number of migraine attacks--especially amongst sufferers who have not been helped by current treatments. MGX 008, which is botanically sourced, provides a new approach to this serious problem and we are committed to taking development forward toward approval as a prescription medicine.”

**Contact:** Larry Stenswick

CEO, Migco Pharmaceuticals, Ltd

Phone:+64 3 313 8284 or (mob) +64 21 755900

[stenswick@migco.co.nz](mailto:stenswick@migco.co.nz)

**About Migco**

Migco Pharmaceuticals is developing and commercializing new drug therapies for the prevention and treatment of migraine headaches. Migco's lead compound, MGX-008 is derived from the bark of *Pinus radiata* and represents a new approach to migraine prevention. It has shown promising indications for the prevention of migraine, and opportunities are emerging for the treatment of other neurological conditions including ADHD and Alzheimers. Migco has clinical safety data for its lead compound MGX 008, successful human concept trial and a highly skilled and experienced scientific management and governance team to manage the process through to market.